Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.

[1]  Kō̜ngthưn Lutphō̜n Khwāmthukyāk.  Manual of operations , 2003 .

[2]  M. Abelson.  Allergic Diseases of the Eye , 2001 .

[3]  W. Fokkens,et al.  Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge. , 2001, The Journal of allergy and clinical immunology.

[4]  G. Clough,et al.  Inhibition by glucocorticoids of the mast cell‐dependent weal and flare response in human skin in vivo , 2001, British journal of pharmacology.

[5]  N. Uzuner,et al.  The comparision of the efficacy of fluticasone propionate with cetirizine in perenneal allergic rhinitis , 2001 .

[6]  J. Greiner,et al.  Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. , 2000, Clinical therapeutics.

[7]  S. Holgate,et al.  Tear and conjunctival changes during the allergen-induced early- and late-phase responses. , 2000, The Journal of allergy and clinical immunology.

[8]  D. Spangler,et al.  A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. , 2000, Clinical therapeutics.

[9]  F. Graziano,et al.  Olopatadine inhibits TNFα release from human conjunctival mast cells , 2000 .

[10]  Howes Jf.  Loteprednol etabonate: a review of ophthalmic clinical studies. , 2000, Die Pharmazie.

[11]  N. Sharif,et al.  A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. , 1999, Acta ophthalmologica Scandinavica. Supplement.

[12]  M. Abelson,et al.  Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. , 1999, Acta ophthalmologica Scandinavica. Supplement.

[13]  S. Xu,et al.  Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. , 1999, Archives of ophthalmology.

[14]  M. Hingorani,et al.  Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. , 1998, The Journal of allergy and clinical immunology.

[15]  M. Abelson.  Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  S. Holgate,et al.  Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[17]  T. Zimmerman,et al.  Textbook of ocular pharmacology , 1997 .

[18]  S. Xu,et al.  Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. , 1996, The Journal of pharmacology and experimental therapeutics.

[19]  P. Barnes.  Molecular mechanisms of steroid action in asthma. , 1996, The Journal of allergy and clinical immunology.

[20]  J. Yanni,et al.  The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  M. Jacobson,et al.  Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  M. Abelson,et al.  Differential diagnosis of ocular allergic disorders. , 1993, Annals of allergy.

[23]  S. Bonini,et al.  Allergen dose response and late symptoms in a human model of ocular allergy. , 1990, The Journal of allergy and clinical immunology.

[24]  F. Fraunfelder,et al.  Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. , 1990, American journal of ophthalmology.

[25]  W. Chambers,et al.  Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. , 1990, Archives of ophthalmology.

[26]  J. Clague,et al.  Effect of topical corticosteroids on seasonally induced increases in nasal mast cells , 1988, British medical journal.

[27]  B. Zweiman,et al.  In vivo effects of corticosteroids on human allergic responses. I. Effects of systemic administrations of steroids. , 1987, Annals of allergy.

[28]  Weeke Er.  Epidemiology of hay fever and perennial allergic rhinitis , 1987 .

[29]  M. Kaliner.  Late phase reactions. , 1986, New England and regional allergy proceedings.

[30]  M. Abelson,et al.  Conjunctival eosinophils in allergic ocular disease. , 1983, Archives of ophthalmology.

[31]  N. Mygind,et al.  Intranasal allergen challenge during corticosteroid treatment , 1977, Clinical allergy.